UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Diabetes therapy, 2021-01, Vol.12 (1), p.143-157

2021

Volltextzugriff (PDF)

Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class

Diabetes, obesity & metabolism, 2021-09, Vol.23 (S3), p.30-39

2021

Volltextzugriff (PDF)

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

The Lancet (British edition), 2023-08, Vol.402 (10401), p.504-505

2023

Volltextzugriff (PDF)

Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

Diabetes, obesity & metabolism, 2019-03, Vol.21 (3), p.454-466

2019

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

The lancet. Diabetes & endocrinology, 2017-04, Vol.5 (4), p.251-260

2017

Volltextzugriff (PDF)

Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]

F1000 research, 2020, Vol.9, p.239

2020

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.355-366

2017

Volltextzugriff (PDF)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.442-451

2020

Volltextzugriff (PDF)

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

The New England journal of medicine, 2023-07, Vol.389 (4), p.297-308

2023

Volltextzugriff (PDF)

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

The New England journal of medicine, 2019-08, Vol.381 (9), p.841-851

2019

Volltextzugriff (PDF)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

The New England journal of medicine, 2016-11, Vol.375 (19), p.1834-1844

2016

Volltextzugriff (PDF)

Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply

The New England journal of medicine, 2019-11, Vol.381 (21), p.2076-2077

2019

Volltextzugriff (PDF)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Diabetes, obesity & metabolism, 2018-04, Vol.20 (4), p.889-897

2018

Volltextzugriff (PDF)

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Diabetes care, 2016-02, Vol.39 (2), p.222-230

2016

Volltextzugriff (PDF)

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

Kidney international, 2023-04, Vol.103 (4), p.772-781

2023

Volltextzugriff (PDF)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation (New York, N.Y.), 2022-02, Vol.145 (8), p.575-585

2022

Volltextzugriff (PDF)

A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks

Diabetic medicine, 2021-08, Vol.38 (8), p.e14539-n/a

2021

Volltextzugriff (PDF)

Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells

International journal of molecular sciences, 2024-06, Vol.25 (12), p.6331

2024

Volltextzugriff (PDF)

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Diabetes care, 2018-10, Vol.41 (10), p.2229-2235

2018

Volltextzugriff (PDF)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.73-73, Article 73

2019

Volltextzugriff (PDF)

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Diabetes care, 2018-09, Vol.41 (9), p.1938-1946

2018

Volltextzugriff (PDF)

The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

Atherosclerosis, 2009-02, Vol.202 (2), p.321-329

2009

Volltextzugriff (PDF)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Endocrinology and metabolism (Seoul), 2023-02, Vol.38 (1), p.25-33

2023

Volltextzugriff (PDF)

Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials

Expert opinion on emerging drugs, 2023-01, Vol.28 (1), p.1-15

2023

Volltextzugriff (PDF)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

Diabetes care, 2020-07, Vol.43 (7), p.1546-1552

2020

Volltextzugriff (PDF)

1 – 25 von 634

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(523)
Mit Volltextzugriff
(553)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(384)
Life Sciences & Biomedicine
(334)
Humans
(243)
Male
(139)
Diabetes
(132)
Female
(131)
Endocrinology & Metabolism
(124)
Middle Aged
(103)
Aged
(78)
Adult
(76)
Biological And Medical Sciences
(73)
Diabetes Mellitus
(69)
Medical Sciences
(63)
Type 2 Diabetes
(53)
Diabetes Mellitus, Type 2 - Drug Therapy
(49)
Insulin
(47)
Physical Sciences
(47)
Risk Factors
(43)
Animals
(42)
Diabetes Mellitus, Type 2 - Complications
(40)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks

Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

Suchergebnisse filtern